Skip to main content
. 2022 Feb 16;13:814429. doi: 10.3389/fimmu.2022.814429

Figure 7.

Figure 7

Network of funnel plot for serious adverse events. A, adalimumab; B, adalimumab + DMARD; C, certolizumab; D, certolizumab + DMARD; F, etanercept; G, etanercept + DMARD; H, golimumab; I, golimumab + DMARD; J, infliximab; K, infliximab + DMARD; L, DMARD; DMARD, disease-modifying anti-rheumatic drugs.